In the same month, FDA granted breakthrough approval to Enhertu (fam-trastuzumab deruxtecan-nxki), a HER2-directed ADC for NSCLC and gastric cancer patients with HER2 expression in their tumors. Here, ERBB2 is linked to non-small cell lung carcinoma.